Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.

Abstract

IMPORTANCE:

Androgen deprivation is the standard therapy for patients with advanced or recurrent prostate cancer. However, this treatment causes adverse effects, alters quality of life, and may lead to castration-resistant disease. Intermittent androgen deprivation has been studied as an alternative.

OBJECTIVE:

To conduct a systematic review and meta-analysis comparing the efficacy and tolerability of intermittent vs continuous androgen deprivation therapy in patients with prostate cancer.

DATA SOURCES:

We searched Cochrane CENTRAL, Medline, Embase, Web of Science, Biosis, National Technical Information Service, OpenSIGLE, and Google Scholar from inception of each database through March 2014. References from published guidelines, reviews, and other relevant articles were also considered.

STUDY SELECTION:

We selected randomized clinical trials comparing intermittent vs continuous androgen deprivation therapy in patients with prostate cancer.

DATA EXTRACTION AND SYNTHESIS:

Two reviewers performed study selection, data abstraction, and risk of bias assessment. We calculated hazard ratios (HRs) with the inverse variance method and risk ratios with the Mantel-Haenszel method, using random effect models. A noninferiority analysis was conducted for overall survival with a margin of 1.15 for the upper boundary of the HR. We assessed heterogeneity using the I2 index.

MAIN OUTCOMES AND MEASURES:

Primary outcomes were overall survival and quality of life. Secondary outcomes were cancer-specific survival, progression-free survival, time to castration resistance, skeletal-related events, and adverse effects.

RESULTS:

From 10 510 references, we included 22 articles from 15 trials (6856 patients) published between 2000 and 2013. All but 1 study had an unclear or high risk of bias. We observed no significant difference between intermittent and continuous therapy for overall survival (HR, 1.02; 95% CI, 0.93-1.11; 8 trials, 5352 patients), cancer-specific survival (HR, 1.02; 95% CI, 0.87-1.19; 5 trials, 3613 patients), and progression-free survival (HR, 0.94; 95% CI, 0.84-1.05; 4 trials, 1774 patients). There was minimal difference in patients' self-reported quality of life between the 2 interventions. Most trials observed an improvement in physical and sexual functioning with intermittent therapy.

CONCLUSIONS AND RELEVANCE:

Intermittent androgen deprivation was not inferior to continuous therapy with respect to the overall survival. Some quality-of-life criteria seemed improved with intermittent therapy. Intermittent androgen deprivation can be considered as an alternative option in patients with recurrent or metastatic prostate cancer.

• Authors: Sindy Magnan, Ryan Zarychanski, Laurie Pilote, Laurence Bernier, Michèle Shemilt, Eric Vigneault, Vincent Fradet, Alexis F Turgeon
• Journal: JAMA oncology (JAMA Oncol) Vol. 1 Issue 9 Pg. 1261-9 (Dec 2015) ISSN: 2374-2445 [Electronic] United States
• PMID: 26378418 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)

Chemical References

• Androgen Antagonists
• Antineoplastic Agents, Hormonal

Topics

• Androgen Antagonists (administration & dosage, adverse effects)
• Antineoplastic Agents, Hormonal (administration & dosage, adverse effects)
• Disease Progression
• Disease-Free Survival
• Drug Administration Schedule
• Drug Resistance, Neoplasm
• Humans
• Male
• Prostatic Neoplasms (drug therapy, mortality)
• Quality of Life
• Randomized Controlled Trials as Topic
• Treatment Outcome